Sonnet BioTherapeutics Holdings, Inc. (SONN)

1.7800 +0.0900 (+5.33%) At close: 04:00PM EDT

Sonnet BioTherapeutics Holdings, Inc.

100 Overlook Center
Suite 102
Princeton, NJ 08540
United States
609 375 2227
https://www.sonnetbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Pankaj Mohan Ph.D.	Founder, Chairman, CEO & President	927k	N/A	1965
Dr. John K. Cini Ph.D.	Chief Scientific Officer & Co-Founder	602.48k	N/A	1953
Mr. Jay Cross	Chief Financial Officer	603.42k	N/A	1970
Mr. Donald J. Griffith CPA, CPA	Controller & Director	134.05k	N/A	1949
Ms. Susan Dexter	Chief Technical Officer	N/A	N/A	1955
Dr. Richard T. Kenney FACP, M.D.	Chief Medical Officer	N/A	N/A	1958
Mr. Manuel Dafonseca	Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Corporate governance

Sonnet BioTherapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.